|
End-of-day quote
Egyptian Exchange
2026-08-30
|
5-day change | 1st Jan Change | ||
| 413.02 EGP | -7.19% |
|
-15.25% | +548.89% |
| 08-13 | GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 05-17 | GlaxoSmithKline Q1 consol net profit EGP 4.7 million | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 686M | - | - | - | - | - |
| 1,047B | |||||
| 646B | - | - | - | ||
| 451B | |||||
| 355B | |||||
| 291B |
- Stock Market
- Stocks
- BIOC Stock
- Charts GlaxoSmithKline S.A.E
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
